$0.33 EPS Expected for Avanos Medical Inc (NYSE:AVNS) This Quarter

Analysts predict that Avanos Medical Inc (NYSE:AVNS) will report earnings of $0.33 per share for the current quarter, Zacks reports. Three analysts have provided estimates for Avanos Medical’s earnings, with the lowest EPS estimate coming in at $0.31 and the highest estimate coming in at $0.34. Avanos Medical also reported earnings of $0.33 per share during the same quarter last year. The firm is scheduled to report its next earnings report on Tuesday, February 25th.

On average, analysts expect that Avanos Medical will report full year earnings of $1.07 per share for the current fiscal year, with EPS estimates ranging from $1.03 to $1.17. For the next financial year, analysts forecast that the business will post earnings of $1.37 per share, with EPS estimates ranging from $1.15 to $1.78. Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Avanos Medical.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.02). Avanos Medical had a positive return on equity of 3.92% and a negative net margin of 6.20%. The business had revenue of $171.40 million for the quarter, compared to the consensus estimate of $179.98 million. During the same quarter in the prior year, the company earned $0.37 earnings per share. Avanos Medical’s quarterly revenue was up 3.8% compared to the same quarter last year.

Several analysts recently weighed in on the company. JMP Securities restated a “hold” rating on shares of Avanos Medical in a research report on Wednesday, August 21st. ValuEngine downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 5th. KeyCorp dropped their price objective on Avanos Medical from $51.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Stifel Nicolaus downgraded Avanos Medical from a “buy” rating to a “hold” rating and dropped their target price for the company from $45.00 to $35.00 in a research report on Wednesday, November 6th. Finally, Raymond James downgraded Avanos Medical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $44.80.

Shares of AVNS stock traded up $0.43 on Tuesday, hitting $32.32. 322,668 shares of the company’s stock were exchanged, compared to its average volume of 486,598. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.51 and a quick ratio of 1.84. Avanos Medical has a 12 month low of $31.29 and a 12 month high of $53.45. The stock has a market cap of $1.53 billion, a P/E ratio of 30.08 and a beta of 1.56. The company has a 50 day moving average of $38.93 and a 200 day moving average of $39.71.

A number of institutional investors have recently bought and sold shares of AVNS. RGM Capital LLC raised its position in Avanos Medical by 1,659.3% in the second quarter. RGM Capital LLC now owns 751,523 shares of the company’s stock valued at $32,774,000 after purchasing an additional 708,806 shares during the last quarter. Paradice Investment Management LLC raised its position in Avanos Medical by 17.8% in the second quarter. Paradice Investment Management LLC now owns 1,991,583 shares of the company’s stock valued at $86,853,000 after purchasing an additional 301,082 shares during the last quarter. Invesco Ltd. raised its position in Avanos Medical by 21.0% in the second quarter. Invesco Ltd. now owns 1,637,165 shares of the company’s stock valued at $71,396,000 after purchasing an additional 284,234 shares during the last quarter. Nuveen Asset Management LLC bought a new position in Avanos Medical in the second quarter valued at about $8,718,000. Finally, Macquarie Group Ltd. raised its position in Avanos Medical by 13.0% in the second quarter. Macquarie Group Ltd. now owns 1,234,569 shares of the company’s stock valued at $53,840,000 after purchasing an additional 142,386 shares during the last quarter. Hedge funds and other institutional investors own 94.40% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

See Also: Swap

Get a free copy of the Zacks research report on Avanos Medical (AVNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.